Shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.20 and traded as high as $3.37. Merrimack Pharmaceuticals shares last traded at $3.32, with a volume of 8,665 shares trading hands.
The firm has a 50-day moving average of $3.30 and a 200-day moving average of $3.20.
Merrimack Pharmaceuticals (NASDAQ:MACK) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter.
An institutional investor recently bought a new position in Merrimack Pharmaceuticals stock. Renaissance Technologies LLC bought a new position in shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 33,961 shares of the biopharmaceutical company’s stock, valued at approximately $107,000. Renaissance Technologies LLC owned approximately 0.25% of Merrimack Pharmaceuticals as of its most recent SEC filing. 48.30% of the stock is currently owned by institutional investors and hedge funds.
About Merrimack Pharmaceuticals (NASDAQ:MACK)
Merrimack Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5.
Read More: Cost of equity and a company’s balance sheet
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.